NASDAQ:MBOT - Microbot Medical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.79 0.00 (0.00 %)
(As of 06/22/2018 06:00 AM ET)
Previous Close$0.79
Today's Range$0.7650 - $0.7994
52-Week Range$0.58 - $1.75
Volume213,498 shs
Average Volume279,769 shs
Market Capitalization$33.28 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.05
Microbot Medical logoMicrobot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. It also holds an intellectual property portfolio that comprises 9 patent families, which include 9 patents granted in the United States, 12 patents granted outside the United States, and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.

Receive MBOT News and Ratings via Email

Sign-up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBOT
CUSIPN/A
Phone781-875-3605

Debt

Debt-to-Equity RatioN/A
Current Ratio21.04
Quick Ratio21.04

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$120,000.00
Price / Sales277.29
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book2.93

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,580,000.00
Net MarginsN/A
Return on Equity-48.95%
Return on Assets-46.46%

Miscellaneous

Employees7
Outstanding Shares42,120,000

Microbot Medical (NASDAQ:MBOT) Frequently Asked Questions

What is Microbot Medical's stock symbol?

Microbot Medical trades on the NASDAQ under the ticker symbol "MBOT."

When did Microbot Medical's stock split? How did Microbot Medical's stock split work?

Shares of Microbot Medical reverse split before market open on Monday, May 9th 2016. The 1-12 reverse split was announced on Friday, May 6th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 6th 2016. An investor that had 100 shares of Microbot Medical stock prior to the reverse split would have 8 shares after the split.

How were Microbot Medical's earnings last quarter?

Microbot Medical Inc (NASDAQ:MBOT) posted its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. View Microbot Medical's Earnings History.

When is Microbot Medical's next earnings date?

Microbot Medical is scheduled to release their next quarterly earnings announcement on Monday, June, 25th 2018. View Earnings Estimates for Microbot Medical.

What price target have analysts set for MBOT?

1 equities research analysts have issued twelve-month target prices for Microbot Medical's stock. Their predictions range from $1.75 to $1.75. On average, they anticipate Microbot Medical's share price to reach $1.75 in the next twelve months. View Analyst Ratings for Microbot Medical.

Who are some of Microbot Medical's key competitors?

Who are Microbot Medical's key executives?

Microbot Medical's management team includes the folowing people:
  • Mr. Harel Gadot, Co-Founder, Pres, CEO & Chairman (Age 45)
  • Prof. Moshe Shoham D.Sc., Co-Founder, Scientific Director & Member of Scientific Advisory Board (Age 66)
  • Mr. Yoseph Bornstein, Co-Founder & Director (Age 59)
  • Mr. Yehezkel Himelfarb BSc, MBA, COO, GM & Director (Age 60)
  • Dr. Simon Sharon, Chief Technology Officer

Has Microbot Medical been receiving favorable news coverage?

News stories about MBOT stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Microbot Medical earned a news sentiment score of 0.12 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Microbot Medical?

Shares of MBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Microbot Medical's stock price today?

One share of MBOT stock can currently be purchased for approximately $0.79.

How big of a company is Microbot Medical?

Microbot Medical has a market capitalization of $33.28 million and generates $120,000.00 in revenue each year. Microbot Medical employs 7 workers across the globe.

How can I contact Microbot Medical?

Microbot Medical's mailing address is 25 RECREATION PARK DRIVE UNIT 108, HINGHAM MA, 02043. The biotechnology company can be reached via phone at 781-875-3605 or via email at [email protected]


MarketBeat Community Rating for Microbot Medical (MBOT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  370
MarketBeat's community ratings are surveys of what our community members think about Microbot Medical and other stocks. Vote "Outperform" if you believe MBOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.